Grundläggande statistik
| CIK | 1489077 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Tibet Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| April 6, 2012 |
OMB APPROVAL UNITED STATES OMB Number: 3235-0058 SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 1, 2012 |
Exhibit 99.1 Tibet Pharmaceuticals, Inc. Announces Receipt of Non-Binding “Going Private” Proposal at $3.00 Per Share Shangri-La County, China, March 1, 2012 /PRNewswire-Asia/ - Tibet Pharmaceuticals, Inc. (NASDAQ: TBET - News), an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, today announced that its Boa |
|
| March 1, 2012 |
The following is the letter received from Mr. Yu: EX-99.2 3 v304369ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 The following is the letter received from Mr. Yu: March 1, 2012 Board of Directors Tibet Pharmaceuticals, Inc. Room 1701, 17th Floor Wanchai, Hong Kong Dear Sirs: I, Hong Yu, am pleased to submit this preliminary non-binding proposal (the “Proposal”) to acquire the outstanding ordinary shares of Tibet Pharmaceuticals, Inc. (the “Company”) that |
|
| March 1, 2012 |
Financial Statements and Exhibits, Other Events - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2012 Tibet Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-35038 Not Applicable (State or Other Jurisdiction of Incorp |
|
| February 14, 2012 |
TBET / Tibet Pharmaceuticals, Inc. / Yu Hong - FORM SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Tibet Pharmaceuticals, Inc. (Name of Issuer) Common shares, $0.001 par value per share (Title of Class of Securities) G80649 109 (CUSIP Number) January 18, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| January 18, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2012 Tibet Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-35038 Not Applicable (State or Other Jurisdiction of Inc |
